Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling



Bunglawala, Fazila, Rajoli, Rajith KR ORCID: 0000-0002-6015-5712, Mirochnick, Mark, Owen, Andrew ORCID: 0000-0002-9819-7651 and Siccardi, Marco ORCID: 0000-0002-3539-7867
(2020) Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75 (3). pp. 640-647.

[img] Text
FB_Manuscript_JAC_revised_v3_clean.docx - Author Accepted Manuscript

Download (519kB)

Abstract

Background Only a few antiretroviral drugs (ARVs) are recommended for use during the neonatal period and there is a need for more to be approved to increase treatment and prophylaxis strategies. Dolutegravir, a selective integrase inhibitor, has potential for treatment of HIV infection and prophylaxis of transmission in neonates. Objectives To model the pharmacokinetics of dolutegravir in neonates and to simulate a theoretical optimal dosing regimen. Methods The physiologically based pharmacokinetic (PBPK) model was built incorporating the age-related changes observed in neonates. Virtual neonates between 0 and 28 days were simulated. The model was validated against observed clinical data for raltegravir and midazolam in neonates, prior to the prediction of dolutegravir pharmacokinetics. Results Both raltegravir and midazolam passed the criteria for model qualification, with simulated data within 1.8-fold of clinical data. The qualified model predicted the pharmacokinetics for several multidose regimens of dolutegravir. Regimen 6 involved 5 mg doses with a 48 h interval from Day 1–20, increasing to 5 mg once daily on Week 3, yielding AUC and Ctrough values of 37.2 mg·h/L and 1.3 mg/L, respectively. These exposures are consistent with those observed in paediatric patients receiving dolutegravir. Conclusions Dolutegravir pharmacokinetics were successfully simulated in the neonatal PBPK model. The predictions suggest that during the first 3 weeks of life a 5 mg dose administered every 48 h may achieve plasma exposures needed for therapy and prophylaxis.

Item Type: Article
Uncontrolled Keywords: midazolam, newborn, pediatrics, pharmacokinetics, through concentration, raltegravir, dolutegravir
Depositing User: Symplectic Admin
Date Deposited: 02 Jan 2020 16:14
Last Modified: 19 Jan 2023 00:11
DOI: 10.1093/jac/dkz506
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3068853